Latest revenue
$68.4M
as of 2026-03-31
Latest net income
$-6.3M
as of 2026-03-31
Net margin
-9.2%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $1.77B
- Enterprise value
- $1.77B
- P/E (trailing)
- 107.4×
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $45.97
- 52-wk low
- $28.95
- Beta
- —
- Shares out
- 51.1M
5-year trend
What this company does
Item 1. Business General Information Vericel Corporation is a leading provider of advanced therapies for the sports medicine and severe burn care markets. We have a highly differentiated portfolio of cell therapy and specialty biologic products that combines innovations in biology with medical technologies. We were among the first companies to achieve commercial success in the complex field of cell therapies with treatments that use tissue engineering to regenerate skin and healthy knee cartilage. We currently market two U.S. Food and Drug Administration (“FDA”) approved autologous cell therapy products and one FDA-approved specialty biologic product in the U.S. MACI® is an autologous…
AI summary unavailable — showing raw filing excerpt
Generated from VCEL's filing dated 2026-02-26
Key risks
Table of Contents Item 1A. Risk Factors Summary Risk Factors The following summary highlights some of the principal risks that could adversely affect our business, financial condition or results of operations. This summary is not complete and the risks summarized below are not the only risks we face. These risks are discussed more fully further below. These risks include, but are not limited to, the following: •We may experience significant quarterly and annual fluctuations in our results of operations due to a number of factors. •Our operating results will be harmed if we are unable to effectively manage and sustain our future growth or scale our operations. •We may not be able to manage…
AI summary unavailable — showing raw filing excerpt
Generated from VCEL's filing dated 2026-02-26
Profitability
Gross margin
74.4%
2.6%Operating margin
4.0%
109.9%Net margin
6.0%
36.9%Return on equity
4.7%
31.2%Return on assets
3.4%
41.4%Leverage
Debt / equity
0.38×
22.0%Debt / assets
27.3%
16.0%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $68.4M | +30.1% | $-6.3M | +44.0% | -9.2% |
Q4 2025 2025-12-31 | $92.9M | +23.3% | $23.2M | +17.3% | 25.0% |
Q3 2025 2025-09-30 | $67.5M | +16.6% | $5.1M | +663.2% | 7.5% |
Q2 2025 2025-06-30 | $63.2M | +20.1% | $-553.0K | +88.2% | -0.9% |
Q1 2025 2025-03-31 | $52.6M | +2.6% | $-11.2M | -191.2% | -21.4% |
Q4 2024 2024-12-31 | $75.4M | — | $19.8M | — | 26.3% |
Q3 2024 2024-09-30 | $57.9M | +27.0% | $-901.0K | +75.4% | -1.6% |
Q2 2024 2024-06-30 | $52.7M | +14.7% | $-4.7M | +6.7% | -8.9% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Biological Products, (No Diagnostic Substances) · SIC 2836
Your notes
Keep private notes on VCEL — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$5.3M
Net activity
−$5.3M
Distinct insiders
8
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns VCEL
Institutional value
$981.3M
Total shares held
32.7M
Distinct holders
173
-98 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 7.8M | $249.8M | +58.3K (+0.8%) | Added |
| 2 | Conestoga Capital Advisors, LLC | 2.5M | $79.2M | +208.8K (+9.3%) | Added |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 2.2M | $71.8M | — | New |
| 4 | WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 1.8M | $59.0M | -389.4K (-17.5%) | Trimmed |
| 5 | GENEVA CAPITAL MANAGEMENT LLC | 1.6M | $53.0M | -179.9K (-9.8%) | Trimmed |
| 6 | CONGRESS ASSET MANAGEMENT CO | 1.5M | $48.5M | -157.7K (-9.5%) | Trimmed |
| 7 | SG Capital Management LLC | 1.2M | $38.9M | — | New |
| 8 | VANGUARD PORTFOLIO MANAGEMENT LLC | 991.6K | $31.9M | — | New |
| 9 | DIMENSIONAL FUND ADVISORS LP | 844.8K | $27.2M | +29.1K (+3.6%) | Added |
| 10 | Champlain Investment Partners, LLC | 815.2K | $26.2M | -213.7K (-20.8%) | Trimmed |
| 11 | Allspring Global Investments Holdings, LLC | 678.0K | $22.1M | -21.7K (-3.1%) | Trimmed |
| 12 | abrdn plc | 684.1K | $22.0M | +100.2K (+17.2%) | Added |
| 13 | FEDERATED HERMES, INC. | 627.5K | $20.2M | -14.6K (-2.3%) | Trimmed |
| 14 | TimesSquare Capital Management, LLC | 578.3K | $18.6M | -52.9K (-8.4%) | Trimmed |
| 15 | JANE STREET GROUP, LLC | 409.9K | $13.2M | — | New |
| 16 | SEI INVESTMENTS CO | 360.7K | $11.6M | +128.5K (+55.3%) | Added |
| 17 | VANGUARD FIDUCIARY TRUST CO | 351.2K | $11.3M | — | New |
| 18 | JPMORGAN CHASE & CO | 326.4K | $10.0M | -9.6K (-2.9%) | Trimmed |
| 19 | Invesco Ltd. | 294.2K | $9.5M | +3.2K (+1.1%) | Added |
| 20 | Bank of New York Mellon Corp | 269.8K | $8.7M | -14.7K (-5.2%) | Trimmed |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once VCEL's latest filing finishes processing.